Benchmark starts LeMaitre Vascular at Buy

Benchmark initiates LeMaitre Vascular (LMAT +2%) at Buy.

"The company's well-established position within the vascular surgeon community, and its focus on niche products that typically do not attract competition from the industry giants, give the company a bit of a home field advantage," analyst Jan Wald says, adding that "10%+ annual revenue growth and a $0.12 annual dividend provides investors with reasons to own the stock."

Price target is $9, representing a 28% upside from Wednesday's close.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs